37 patients with coxarthrosis are treated with 6ml of PRP (platelet rich plasma), obtained from blood extracted from patients in the 20 minutes prior to infiltration thereof.

For PRP administration:

• The injection should be performed at room temperature.
• The administration should be carried out under aseptic conditions.
• The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.
• The PRP is injected into the synovial space.

37 patients with coxarthrosis are treated with a pre-filled syringe of hyaluronic acid 60mg / 6ml (Synvisc-One ®).

It is necessary to remove synovial fluid before injecting Hylan G-F 20.

• The injection should be performed at room temperature.
• The administration should be carried out under aseptic conditions.
• The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.
• The Hylan G-F 20 is injected into the synovial space.
• After injecting Hylan G-F 20 the patient should stand 5 minutes.

Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).

The patient assesses the sensation of pain following a horizontal visual analog scale (EVA) with values between 0 ("no pain") and the value 100 ("excruciating pain"). The records taken are recorded in the medical record of the patient.

It is a questionnaire developed to evaluate hip surgery or replacement. It is widely used for evaluation of hip disorders and treatment methods.

It is a standardized questionnaire, widely used for assessment of both knee and hip osteoarthritis. It consists of five items for assessing pain (range 0-20), two items that assess the stiffness (range 0-8) and 17 items that evaluate the functionality of the joint (range 0-68).

All adverse events (AEs) are recorded in the case report data from the time that the patient sign the informed consent, indicating the nature of adverse events and their description in both: the experimental group and the comparator.